Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1979
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1982 2
1988 1
1990 1
1991 2
1993 1
1994 4
1995 3
1996 1
1998 6
1999 9
2000 2
2001 6
2002 9
2003 9
2004 12
2005 12
2006 8
2007 4
2008 6
2009 14
2010 8
2011 10
2012 6
2013 14
2014 9
2015 10
2016 9
2017 9
2018 10
2019 5
2020 5
2021 8
2022 4
2023 6
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

219 results

Results by year

Filters applied: . Clear all
Page 1
Advances in Treatment of Dyslipidemia.
Dybiec J, Baran W, Dąbek B, Fularski P, Młynarska E, Radzioch E, Rysz J, Franczyk B. Dybiec J, et al. Int J Mol Sci. 2023 Aug 27;24(17):13288. doi: 10.3390/ijms241713288. Int J Mol Sci. 2023. PMID: 37686091 Free PMC article. Review.
These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). ...Among these promising pharmaceuticals, we highlight alirocumab, bempedoic acid, antisense oligonuc …
These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density l …
Lipoprotein(a) and Cardiovascular Diseases - Revisited.
Jang AY, Han SH, Sohn IS, Oh PC, Koh KK. Jang AY, et al. Circ J. 2020 May 25;84(6):867-874. doi: 10.1253/circj.CJ-20-0051. Epub 2020 Apr 24. Circ J. 2020. PMID: 32336721 Free article. Review.
Two decades ago, it was recognized that lipoprotein(a) (Lp(a)) concentrations were elevated in patients with cardiovascular disease (CVD). However, the importance of Lp(a) was not strongly established due to a lack of both Lp(a)-lowering therapy and evidence that reducing …
Two decades ago, it was recognized that lipoprotein(a) (Lp(a)) concentrations were elevated in patients with cardiovascular disease ( …
Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia.
Poliakova T, Wellington CL. Poliakova T, et al. Mol Neurodegener. 2023 Nov 16;18(1):86. doi: 10.1186/s13024-023-00671-y. Mol Neurodegener. 2023. PMID: 37974180 Free PMC article. Review.
Humans have a peripheral lipoprotein profile where low-density lipoproteins (LDL) represent the dominant lipoprotein fraction and high-density lipoproteins (HDL) represent a minor lipoprotein fraction. Elevated LDL-cholesterol (LDL-C) levels are well-establis …
Humans have a peripheral lipoprotein profile where low-density lipoproteins (LDL) represent the dominant lipoprotein fraction and high-densi …
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ, Zamorano JL, Parhofer KG. Chapman MJ, et al. Pharmacol Ther. 2022 Sep;237:108172. doi: 10.1016/j.pharmthera.2022.108172. Epub 2022 Mar 15. Pharmacol Ther. 2022. PMID: 35304222 Free article. Review.
Recent findings from the Progression of Early Subclinical Atherosclerosis (PESA) cohort in Spain showed that even in apparently healthy, middle-aged individuals without a history of cardiovascular (CV) risk, elevated triglyceride levels are associated with subclinic …
Recent findings from the Progression of Early Subclinical Atherosclerosis (PESA) cohort in Spain showed that even in apparently healthy, mid …
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. Stroes ES, et al. Eur Heart J. 2015 May 1;36(17):1012-22. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18. Eur Heart J. 2015. PMID: 25694464 Free PMC article. Review.
Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7-29% in registries and observational studies. ...In people with SAMS, the Panel recommends the use of a maxi …
Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK le
The pathophysiology of excess plasma-free cholesterol.
Gillard BK, Rosales C, Gotto AM Jr, Pownall HJ. Gillard BK, et al. Curr Opin Lipidol. 2023 Dec 1;34(6):278-286. doi: 10.1097/MOL.0000000000000899. Epub 2023 Sep 25. Curr Opin Lipidol. 2023. PMID: 37732779 Free PMC article. Review.
In most clinical settings, plasma HDL-cholesterol is determined as a sum of free cholesterol and cholesteryl ester, two molecules with vastly different metabolic itineraries. ...SUMMARY: Collective consideration of the human and mouse data suggests that clini …
In most clinical settings, plasma HDL-cholesterol is determined as a sum of free cholesterol and cholesteryl ester, two …
Microdomains, Inflammation, and Atherosclerosis.
Sorci-Thomas MG, Thomas MJ. Sorci-Thomas MG, et al. Circ Res. 2016 Feb 19;118(4):679-91. doi: 10.1161/CIRCRESAHA.115.306246. Circ Res. 2016. PMID: 26892966 Free PMC article. Review.
Elevated levels of cholesteryl ester (CE)-enriched apoB containing plasma lipoproteins lead to increased foam cell formation, the first step in the development of atherosclerosis. Unregulated uptake of low-density lipoprotein cholesterol by circulating
Elevated levels of cholesteryl ester (CE)-enriched apoB containing plasma lipoproteins lead to increased foam cell form
Did we abandon probucol too soon?
Yamashita S, Masuda D, Matsuzawa Y. Yamashita S, et al. Curr Opin Lipidol. 2015 Aug;26(4):304-16. doi: 10.1097/MOL.0000000000000199. Curr Opin Lipidol. 2015. PMID: 26125504 Review.
RECENT FINDINGS: Recently, the mechanisms for the pharmacologic actions of probucol have been elucidated at the molecular level with a special focus on HDL metabolism and its functions. Probucol enhances plasma cholesteryl ester transfer protein activity and hepatic …
RECENT FINDINGS: Recently, the mechanisms for the pharmacologic actions of probucol have been elucidated at the molecular level with …
Is cholesterol a risk factor for breast cancer incidence and outcome?
Ben Hassen C, Goupille C, Vigor C, Durand T, Guéraud F, Silvente-Poirot S, Poirot M, Frank PG. Ben Hassen C, et al. J Steroid Biochem Mol Biol. 2023 Sep;232:106346. doi: 10.1016/j.jsbmb.2023.106346. Epub 2023 Jun 13. J Steroid Biochem Mol Biol. 2023. PMID: 37321513 Review.
The role of cholesterol in breast cancer is complex, and some studies have suggested that elevated cholesterol levels may be associated with an increased risk of developing breast cancer, while others have found no significant association. On the other …
The role of cholesterol in breast cancer is complex, and some studies have suggested that elevated cholesterol level
Antisense Oligonucleotides Targeting Lipoprotein(a).
Langsted A, Nordestgaard BG. Langsted A, et al. Curr Atheroscler Rep. 2019 May 20;21(8):30. doi: 10.1007/s11883-019-0792-8. Curr Atheroscler Rep. 2019. PMID: 31111240 Review.
The European Atherosclerosis Society recommends screening for elevated lipoprotein(a) levels in high-risk patients. Different therapies have been suggested and some are used to treat elevated lipoprotein(a) levels such as niacin, PCSK9 inhibitors, and …
The European Atherosclerosis Society recommends screening for elevated lipoprotein(a) levels in high-risk patients. Different …
219 results